TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
RAPP

Rapport Therapeutics, Inc.

Healthcare · Biotechnology

34.10$ -17.7% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet RAPP
Line item 2022 2023 2024 2025
– +391.8% +102.6% +62.7%
– +382.5% +105.3% +60.9%
– +125.2% -19.0% -7.3%
– +373.3% +107.0% +60.7%
– +1,396.6% -94.7% +192.2%
– +429.3% -0.4% +117.3%
– – +10.0% +273.8%
– +72.6% -21.9% +114.4%
– -231.4% – +58.7%
– – – –
– -10.1% +14.7% +126.5%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?